Frontline treatment of localized osteosarcoma without methotrexate

Cancer

Volumn 117, Issue 12, 2011, Pages 2770-2778

  Daw, Najat C ^a,b,e   Neel, Michael D ^a   Rao, Bhaskar N ^a,b   Billups, Catherine A ^a   Wu, Jianrong ^a   Jenkins, Jesse J ^a   Quintana, Juan ^c   Luchtman Jones, Lori ^d,f   Villarroel, Milena ^c   Santana, Victor M ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^c HOSPITAL LUIS CALVO MACKENNA   (Chile)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

carboplatin; cisplatin; encephalopathy; ifosfamide; methotrexate; osteosarcoma; outcome; renal failure; treatment

Indexed keywords

CARBOPLATIN; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE; METHOTREXATE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AMINOTRANSFERASE BLOOD LEVEL; AMPUTATION; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER SURGERY; CHILD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROLYTE URINE LEVEL; EVENT FREE SURVIVAL; FEBRILE NEUTROPENIA; FEMALE; GLOMERULUS FILTRATION RATE; GRANULOCYTOPENIA; HEARING LOSS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERBILIRUBINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTENSION; INFECTION; LIMB SALVAGE; LIVER TOXICITY; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OSTEOSARCOMA; OTOTOXICITY; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEPSIS; SIDE EFFECT; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT RESPONSE; VOMITING; WOUND INFECTION;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CARBOPLATIN; CHILD; CHILD, PRESCHOOL; CISPLATIN; DOXORUBICIN; FEMALE; HUMANS; IFOSFAMIDE; MALE; OSTEOSARCOMA;

EID: 79958819638     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25715     Document Type: Article

References (35)

1. Meyers PA, Heller G, Healey JH, et al. Osteogenic sarcoma with clinically detectable metastasis at initial presentation. J Clin Oncol. 1993; 11: 449-453. (Pubitemid 23071040)
2. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002; 20: 776-790. (Pubitemid 34111386)
3. Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005; 23: 2004-2011. (Pubitemid 46211380)
4. Fuchs N, Bielack SS, Epler D, et al. Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol. 1998; 9: 893-899. (Pubitemid 28440449)
5. Goorin AM, Schwartzentruber DJ, Devidas M, et al. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol. 2003; 21: 1574-1580. (Pubitemid 46594112)
6. Bacci G, Briccoli A, Ferrari S, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli's 4th protocol. Eur J Cancer. 2001; 37: 2030-2039. (Pubitemid 32938106)
7. Crews KR, Liu T, Rodriguez-Galindo C, et al. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma. Cancer. 2004; 100: 1724-1733. (Pubitemid 38456352)
8. Meyer WH, Pratt CB, Poquette CA, et al. Carboplatin/ifosfamide window therapy for osteosarcoma: results of the St Jude Children's Research Hospital OS-91 trial. J Clin Oncol. 2001; 19: 171-182. (Pubitemid 32063494)
9. Ferguson WS, Harris MB, Goorin AM, et al. Presurgical window of carboplatin and surgery and multidrug chemotherapy for the treatment of newly diagnosed metastatic or unresectable osteosarcoma: Pediatric Oncology Group Trial. J Pediatr Hematol Oncol. 2001; 23: 340-348. (Pubitemid 32845659)
10. Daw NC, Billups CA, Rodriguez-Galindo C, et al. Metastatic osteosarcoma. Cancer. 2006; 106: 403-412.
11. Bramwell VH, Burgers M, Sneath R, et al. A comparison of 2 short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. J Clin Oncol. 1992; 10: 1579-1591. (Pubitemid 23057988)
12. Souhami RL, Craft AW, Van der Eijken JW, et al. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet. 1997; 350: 911-917. (Pubitemid 27420527)
13. Epelman S, Seibel N, Melaragno R, et al. Treatment of newly diagnosed high grade osteosarcoma (OS) with ifosfamide (IFOS), adriamycin (ADR) and cisplatin (CDP) without high dose methotrexate [abstract]. Med Pediatr Oncol. 1996; 27: 226. Abstract O-61.
14. Stoller RG, Hande KR, Jacobs SA, Rosenberg SA, Chabner BA., Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med. 1977; 297: 630-634. (Pubitemid 8200049)
15. Rodman JH, Maneval DC, Magill HL, Sunderland M., Measurement of Tc-99m DTPA serum clearance for estimating glomerular filtration rate in children with cancer. Pharmacotherapy. 1993; 13: 10-16. (Pubitemid 23045279)
16. Marina NM, Rodman J, Shema SJ, et al. Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors. J Clin Oncol. 1993; 11: 554-560. (Pubitemid 23071055)
17. Marina NM, Rodman JH, Murry DJ, et al. Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in treatment of newly diagnosed pediatric solid tumors. J Natl Cancer Inst. 1994; 86: 544-548. (Pubitemid 24111010)
18. Reddick WE, Wang S, Xiong X, et al. Dynamic magnetic resonance imaging of regional contrast access as an additional prognostic factor in pediatric osteosarcoma. Cancer. 2001; 91: 2230-2237. (Pubitemid 32552807)
19. Reddick WE, Bhargava R, Taylor JS, Meyer WH, Fletcher BD., Dynamic contrast-enhanced MR imaging evaluation of osteosarcoma response to neoadjuvant chemotherapy. J Magn Reson Imaging. 1995; 5: 689-694.
20. Huvos AG, Rosen G, Marcove RC., Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement. Arch Pathol Lab Med. 1977; 101: 14-18. (Pubitemid 8190735)
21. Rosen G, Caparros B, Huvos AG, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer. 1982; 49: 1221-1230. (Pubitemid 12187826)
22. Makuch RW, Simon RM., Sample size considerations for non-randomized comparative studies. J Chronic Dis. 1980; 33: 175-181. (Pubitemid 10162548)
23. Gehan EA., Design of controlled clinical trials: use of historical controls. Cancer Treat Rep. 1982; 66: 1089-1093. (Pubitemid 12090369)
24. Kaplan E, Meier P., Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
25. Kalbfleisch JD, Prentice RL., The Statistical Analysis of Failure Time Data. New York: John Wiley & Sons; 1980.
26. Gray RJ., A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988; 16: 1141-1154.
27. Schwartz CL, Wexler LH, Devidas M, et al. P9754 therapeutic intensification in non-metastatic osteosarcoma: a COG trial [abstract]. Proc Am Soc Clin Oncol. 2004; 22 (suppl 14): 802s. Abstract 8514.
28. Meyers PA, Schwartz CL, Krailo MD, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival-a report from the Children's Oncology Group. J Clin Oncol. 2008; 26: 633-638. (Pubitemid 351264359)
29. Ferrari S, Smeland S, Mercuri M, et al. Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol. 2005; 23: 8845-8852. (Pubitemid 46211531)
30. Meyers PA, Heller G, Healey J, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol. 1992; 10: 5-15.
31. Provisor AJ, Ettinger LJ, Nachman JB, et al. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol. 1997; 15: 76-84. (Pubitemid 27020560)
32. Janeway KA, Grier HE., Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects. Lancet Oncol. 2010; 11: 670-678.
33. Bacci G, Ferrari S, Bertoni F, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol. 2000; 18: 4016-4027. (Pubitemid 32038393)
34. Picci P, Sangiorgi L, Rougraff BT, Neff JR, Casadei R, Campanacci M., Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcoma. J Clin Oncol. 1994; 12: 2699-2705. (Pubitemid 24379659)
35. Rodriguez-Galindo C, Shah N, McCarville MB, et al. Outcome after local recurrence of osteosarcoma: the St. Jude Children's Research Hospital experience (1970-2000). Cancer. 2004; 100: 1928-1935. (Pubitemid 38541499)